Skip to main content
. 2022 Jan 26;14(1):40–53. doi: 10.4330/wjc.v14.i1.40

Table 6.

Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes 8: Comparison to Organization to Assess Strategies in Ischemic Syndromes 5 major bleeding (< 48 h of percutaneous coronary intervention)

Adjusted major bleeding rate OASIS 5 PCI
OASIS 5 PCI
Fondaparinux
Enoxaparin
Major bleeding
Major bleeding
FUTURA 1.5% 3.6%
Standard dose UFH 1.1% (0.6-2.1)
FUTURA
Low dose UFH 1.2% (0.6-2.2)

PCI: Percutaneous coronary intervention; FUTURA: Fondaparinux with unfractionated heparin; OASIS: Organization to Assess Strategies in Ischemic Syndromes; UFH: Unfractionated heparin.